LB Pharmaceuticals

tenant

trial

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

NCTId NCT00208819

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 4 · Completed

Enrollment 50 (estimated)

Sponsored by Emory University

Synthesized from structured facts only — each point cited above.

Design & status

Phase

Phase 4

Status

Completed

Enrollment

50 (estimated)

Study type

Interventional

Allocation

Randomized

Model

Parallel

Masking

None

Start

2003-09

Primary completion

—

Eligibility

ALL · 65 Years

Interventions & indications

Drugs

Risperidone Quetiapine Olanzapine divalproex

Indications

Psychomotor Agitation Dementia, Alzheimer Type Dementia Senile Dementia, Alzheimer Type Alzheimer Disease Dementia Psychotic Disorders Alzheimer Disease Mental Disorders

Sponsors

Emory UniversityLead Sponsor

Abbott Medical DevicesCollaborator

Investigators

1

Larry E. Tune, MD, MASPrincipal Investigator

Sites

1 total

Atlanta, United States

Facts & assertions

3 sourced

Enrollment

50

Phase

PHASE4

Status

COMPLETED

relationships

The graph out of here

drug

drug

drug

drug

drug

lead_sponsor

Emory University

company

collaborator

Abbott Medical Devices

company

indication

Psychomotor Agitation

indication

Dementia, Alzheimer Type

indication

indication

investigator

Larry E. Tune, MD, MAS

person